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Objectives. To examine the feature of men who beneﬁt from dose escalation of naftopidil for lower urinary tract symptoms
(LUTSs). Methods. Based on the IPSS, men reporting LUTS were prospectively studied using 50mg/day of naftopidil for the ﬁrst 4
weeks; satisﬁed patients continued its 50mg/day (n = 11), and those reporting unsatisfactory improvement received its 75mg/day
(n = 35)forthenext 4weeks. Results.The75mggroupshowed improvement inthetotalIPSSand QOLscoreinadose-dependent
manner (at 4 weeks: P<. 001, at 4 weeks versus 8 weeks: P<. 05). In the 50mg group, both scores reduced at 4 weeks, thereafter
unchanged. The baseline slow stream score alone was higher in the 75mg group (P = .013). The rate of change in the QOL score
during the initial 4 weeks (ΔQOL) and Δnocturia was smaller in the 75mg group (P<. 05). Conclusions.M e nw i t hh i g hs l o w
stream score and unsatisfactory improvement in nocturia may beneﬁt from dose escalation of naftopidil.
1.Introduction
Lower urinary tract symptoms (LUTSs) impair the health-
related quality of life (QOL) [1–4]. The prevalence and
severity of LUTS increase with age, and many middle-aged
to elderly people show various levels of LUTS [4, 5]. Voiding
symptoms are more popular in men than in women [6, 7],
and,correspondingly,thecausativeconditionassociatedwith
male LUTS is represented by benign prostatic hyperplasia
(BPH). The treatment theory for BPH is thus targeting
voiding symptoms mainly based on two types of lower uri-
nary tract obstruction: mechanical urinary tract obstruction
by the enlarged prostate and functional constriction of the
urethral and prostatic smooth muscle via sympathetic α1-
stimulants/α1-adrenoreceptors interaction. Accordingly, α1-
adrenoreceptorantagonistsarewidelyappliedastheﬁrst-line
in current therapeutic practice for BPH. On the other hand,
it is also important to manage not only voiding symptoms
but also storage symptoms in men with LUTS. Alpha1-
adrenoceptor antagonists have also been known to alleviate
storage symptoms, although the mechanism of storage
symptoms as well as how mentioned agents are involved in
improvement of them has not been fully elucidated [3, 4, 7,
8].
Naftopidil has a high aﬃnity for α1D-adrenoceptor; α1-
adrenoceptorantagonistswithhighselectivityforα1A-adren-
oceptors has been thought to be more eﬀective in treatment
of LUTS [8, 9], whereas recent basic and clinical studies
also showed the therapeutic potential of α1-adrenoceptor
antagonists with high selectivity for α1D-adrenoceptors [10].
Indeed, naftopidil has been applied for men having BPH-
associated LUTS and has been regarded as a second-
generation α1-adrenoceptor antagonist [11]. While α1A-ad-
renoceptors play a critical role in relaxing smooth muscle
of the prostate and urethra and improve obstructive/voiding
symptoms [8, 9], storage and bladder irritability symptoms2 Advances in Urology
are predominantly α1D-adrenoceptor-associated conditions
[10]. Although unfavorable/adverse eﬀects by naftopidil
on blood pressure/cardiovascular system are infrequent,
50mg/dayofperoralnaftopidilistheinitialtreatmentsetting
in Asian populations generally [11]. A recent case-control
study reported that the setting of 75mg/day showed a
higher therapeutic eﬃcacy compared with that of 25 or
50mg/day of naftopidil [11, 12]. Yet, there have been few
studies that examined the treatment eﬃcacy and safety of
75mg/day of peroral naftopidil in longitudinal comparison
with those of 50mg/day; such approach may possibly
characterize patients who beneﬁt from dose escalation of
naftopidil without compromising safety in clinical practice.
Thereby, key/leading symptoms or factors impairing LUTS-
related QOL may be underscored. In the present study, we
prospectively studied men having moderate-to-severe LUTS
in a longitudinal approach with dose escalation from 50mg
to 75mg of naftopidil once a day to examine the feature
of patients who prefer and beneﬁt from dose escalation of
naftopidil,andtoidentifywhichsymptomandimprovement
thereof reﬂect the LUTS-related QOL.
2. Methods
2.1. Patients. In total, 53 patients who presented at Niigata
University Hospital and associated institutions with the
International Prostate Symptom Score (IPSS) of 8 or higher
were prospectively enrolled between September 2007 and
July 2009. The performance status was good (World Health
Organization Performance Status Score zero) in all of them.
The study had a longitudinal design, and the procedure for
this research project was approved by the Ethics Committee
ofourinstitution.Informedconsentwasobtainedfromallof
the patients. Exclusion criteria were patients with a history
of bladder cancer, prostate cancer, or pelvic irradiation,
along with those diagnosed with bladder stone, untreated
deﬁnite urinary tract infections, and neurogenic bladder.
Patients who had already been treated for lower urinary
tract dysfunctions with surgery or any intervention were also
excluded.
2.2. Examinations and Questionnaires. At the initial visit,
the patients ﬁlled in the baseline International Prostate
Symptom Score (IPSS) sheets handed to them when visiting
the outpatient clinic. General blood and biochemical exam-
inations, urinalysis, residual urine volume measurement
usinganultrasonographicinstrument,andultrasonographic
examinations of the upper and lower urinary tracts were
performed in all patients. Those with microscopic hematuria
received a urinary cytological examination; all of them
showed a normal smear.
2.3.DoseEscalationofNaftopidilandLongitudinalAssessment
of IPSS. All patients were treated with 50mg of naftopidil
once a day for the ﬁrst 4 weeks and reported the IPSS
after administration. Patients without adverse events who
reported unsatisfactory improvement of LUTS and preferred
advanced treatment based on a question “are you satisﬁed
with your current urinary state, yes or no?” received 75mg of
naftopidil once a day for the next 4 weeks (75mg group) and
reported the IPSS again following treatment (8 weeks after
starting treatment). Those having satisfactory improvement
with the initial treatment at 50mg/day continued 50mg of
naftopidil(50mggroup)andalsoreportedIPSSinthenext4
weeks (8 weeks after starting treatment). Adverse events were
assessed at every visit.
2.4.StatisticalAnalysis. Inadditiontothechi-squaretestand
pared t-test, the Welch-corrected t-test was used to compare
unpaired parameters between two subgroups, and Tukey’s
honestly signiﬁcant diﬀerence (HSD) was used for the
comparison of values among 3 or more subgroups. Corre-
lations between parameters were analyzed using Spearman’s
rank correlation coeﬃcient analysis (rs). Multilinear logistic
regression model, which produces prediction formula with
a smaller margin of error, was used for the identiﬁcation
of independent signiﬁcant correlations among continuous
or stepwise variables. The test was two-sided, and P<
.05 was considered signiﬁcant. All analyses were performed
using SPSS version 11.0J (SPSS Inc., Chicago, IL, USA) in a
Windows-based computer.
3. Results
3.1. Adverse Events and Patients’ Demographics. Data were
available in 53 patients, and, of these, treatment was discon-
tinued due to adverse eﬀects at the dose of 50mg/day and
75mg/day in 5 and 2 patients (9.4% and 5.4%), respectively,
at 50mg: dizziness in 2, slight stagger in 1, orthostatic
hypotension in 1, and orthostatic syncope in 1, and the
eventssoondisappearedbydrugdiscontinuation;at75mg,2
patients reported slight stagger, and these disappeared soon
after dose reduction to 50mg. Excluding these subjects, 46
patientscomprisedtheﬁnalstudygroups,and35and11men
were included in the 75mg and 50mg groups, respectively.
Demographics and the baseline IPSS of the patients were
shown in Table 1. Patients’ age, prostate volume, residual
urine volume, total IPSS, and storage, voiding, and quality-
of-life (QOL) scores were equally distributed between the
75mg and 50mg groups (Table 1). For each domain of the
baseline IPSS, the score for slow stream alone was higher in
the 75mg group than in the 50mg group (3.6±1.6 versus
2.1±1.9, P = .013).
3.2. Alteration of the IPSS and QOL Score during the Obser-
vation Period. The alteration of the total IPSS, storage score,
voiding score, postmicturition score (domain for feeling of
incomplete emptying), and QOL score was presented in
Figures 1(a)–1(e). The 75mg group showed improvement in
alloftheseinatime-dependentanddose-dependentmanner
(baseline versus 4 weeks after treatment: P<. 001 in all; 4
weeks after treatment versus 8 weeks after treatment: P =
.019, P = .057, P = .047, P = .057, and P = .003, resp.),
although the diﬀerence in the storage and postmicturition
scores were of borderline signiﬁcance between at 4 weeks
and 8 weeks (Figures 1(b) and 1(d)). In the 50mg group,Advances in Urology 3
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Figure1:AlterationofthetotalIPSS(a),storage(b),voiding(c),postmicturition(domainforfeelingofincompleteemptying)(d),andQOL
(e) scores in men with dose escalation from 50mg/day to 70mg/day of naftopidil (75mg group) and those maintained with its 50mg/day
(50mg group).
all of these scores reduced 4 weeks after treatment compared
with those at baseline (P = .004, P = .015, P = .020,
P = .041, and P<. 001, resp.); these scores were not diﬀerent
between 4 weeks and 8 weeks after treatment (Figures 1(a)–
1(e)), although the diﬀerence was of borderline signiﬁcance
regarding the QOL score (P = .053).
3.3. Analyses Concerning the Feature of the 75mg Group. We
furtherstudiedtheclinicalfeatureofmeninthe75mggroup
in comparison with the 50mg group to identify those who
beneﬁt from 75mg treatment. We hypothesized that the low
degree of satisfaction concerning some speciﬁc symptoms
with 50mg/day of naftopidil might be associated with the
motive for patients to select the dose escalation. We ﬁrst veri-
ﬁedthattherateofchangeintheQOLscoreduringtheinitial
4w e e k s( ΔQOL) in the 75mg group was smaller than that in
the 50mg group (P = .045, Figure 2, right side columns).
We subsequently analyzed the rate of change in each domain
of the IPSS during the initial 4 weeks to examine which Δ
domain potentially reﬂected ΔQOL, and found that the rate
of change in nocturia (Δnocturia) alone was smaller in the
75mg group than in the 50mg group (P = .046, Figure 2).
With Spearman’s rank correlation coeﬃcient analysis, the
baselinescorefornocturiawascorrelatedwiththeQOLscore
in the overall patients (rs. = 0.459, P = .002) and in the
75mg group (rs. = 0.462, P = .007), but the relationshipAdvances in Urology 5
Table 1: Patients’ demographics and the baseline International Prostate Symptom Score (IPSS).
Total 75mg group 50mg group P value
(n = 46) (n = 35) (n = 11) (75mgversus50mg)
Age, mean (years) 71.7 ± 9.4 72.1 ± 9.2 70.2 ± 10.5 .559
Prostate volume, mean (mL) 31.7 ± 24.8 34.6 ± 24.9 25.0 ± 24.8 .403
Residual urine, mean (mL) 24.0 ± 41.5 24.5 ± 43.3 22.4 ± 36.1 .899
IPSS total 17.2 ± 6.9 18.1 ± 7.2 14.2 ± 5.1 .100
Storage score 7.7 ± 3.5 7.8 ± 3.6 7.5 ± 3.3 .780
Pollakisuria 3.0 ± 1.6 3.1 ± 1.6 2.8 ± 1.8 .602
Urgency 1.9 ± 1.8 2.0 ± 1.9 1.5 ± 1.4 .469
Nocturia 2.8 ± 1.3 2.7 ± 1.3 3.1 ± 1.4 .385
Voiding score 7.2 ± 4.3 7.9 ± 4.3 5.0 ± 3.5 .051
Intermittency 2.2 ± 1.9 2.4 ± 2.0 1.7 ± 1.7 .334
Slow stream 3.2 ± 1.8 3.6 ± 1.6 2.1 ± 1.9 .013
Straining 1.7 ± 1.8 1.9 ± 1.9 1.2 ± 1.3 .242
Postmicturition score∗ 2.3 ± 1.8 2.5 ± 1.9 1.7 ± 1.6 .233
QOL score 4.8 ± 1.0 4.9 ± 1.0 4.6 ± 1.1 .442
Score: mean ± standard deviation (SD); postmicturition score∗, domain for feeling of incomplete emptying.
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Figure 2: The rate of change in the QOL score (ΔQOL) and each domain of the IPSS (Δ each domain) with 50mg/day of naftopidil during
the ﬁrst 4 weeks.
was not signiﬁcant in the 50mg group despite the high
correlation coeﬃcient (rs. = 0.482, P = .127). The score for
nocturia 4 weeks after treatment was also correlated with the
QOL score in the overall patients (rs. = 0.459, P = .002)
and in the 75mg group (rs. = 0.475, P = .006); the rela-
tionship was not signiﬁcant in the 50mg group with the high
correlation coeﬃcient (rs. = 0.508, P = .108). Δnocturia
was correlated with ΔQOL in the overall patients (rs. =
0.562, P<. 001) and both in the 75mg and 50mg groups
(rs. = 0.437, P = .011 and rs. = 0.663, P = .036, resp.).
With multivariate analysis employing multilinear logistic
regression model, Δnocturia alone was an independent value
correlated with ΔQOL in all 46 patients (r = 0.542, P =
.006). In each group, however, this model failed to identify
signiﬁcant independent correlations (data not shown).
4. Discussion
Funahashi and colleagues reported the eﬃcacy of 75mg/day
of naftopidil in patients with BPH who did not show
improvement with 50mg/day of naftopidil [12]. In their
study,40ofthe122patientsreceived75mg/dayofnaftopidil;
prostate volume of the 9 responders was larger than that of
the 31 nonresponders, and the authors concluded possible
advantage of the dose escalation to 75mg/day of naftopidil
in patients with BPH. The present study design was similar
to that of Funahashi et al. [12] , but, in our study, a higher
fraction of patients (76%) experienced dose escalation based
on the satisfaction in improvement of LUTS. We showed that
the total IPSS, storage, voiding, postmicturition, and QOL
scores in the 75mg group decreased in a time-dependent6 Advances in Urology
and dose-dependent manner, although the diﬀerence in
the postmicturition and storage scores was of borderline
signiﬁcance between at 4 weeks and 8 weeks (Figure 1(a)–
1(e)).Inthe50mggroup,thesescoresweresimilarbetween4
weeks and 8 weeks after treatment, possibly suggesting dose-
dependent rather than time-dependent eﬀects of naftopidil
in the 75mg group; the number of patients enrolled in
the 50mg group was small to draw a deﬁnite conclusion.
Additionally, adverse eﬀects did not diﬀer between the two
settings, supporting the safety of 75mg/day of this agent.
The present results showed that patients selecting 75mg
therapy had higher scores for the slow stream domain at
baseline (mean 3.6, Table 1), and those with a baseline
score of 3 or higher for slow stream are probably feasible
candidates who beneﬁt from dose escalation of naftopidil.
Additionally, the 75mg group seemingly had a higher IPSS
voiding score at baseline and larger prostate volume than
the 50mg group; the small number of patients in the
50mg group might lead to the bias. Thus, it is suggested
that severer bladder outlet resistance was associated with
unsatisfactory improvement of symptoms during 50mg
treatment in the 75mg group. Naftopidil also has an α1A-
adrenogenic activity, although it is weaker than that of
other α1-adrenoreceptor antagonists such as tamsulosin.
Naftopidil is α1-adrenoreceptor selective in the order of
α1D >α 1A ≥ α1B, and it has about 3-fold selectiv-
ity for α1D-adrenoreceptors compared with that for α1A-
adrenoreceptors [8], suggesting that dose escalation of
naftopidil possibly could evoke more α1A-adrenoreceptor
reactions in relaxing the prostate/urethra smooth muscle
and alleviating voiding symptoms. For men with bladder
outlet obstruction or reporting moderate-to-severe voiding
symptoms, the initial appropriate dose of naftopidil may be
75mg/day.
Our study also suggested the dose-dependent eﬃcacy
of naftopidil for storage symptoms in the 75mg groups
(Figure 1(b)), although the diﬀerence was of borderline
signiﬁcance between 4 weeks and 8 weeks after treatment.
Interestingly, analyses for the degree of satisfaction showed
that ΔQOL during the ﬁrst 4 weeks with 50mg/day of
naftopidil in the 75mg group was smaller than that in the
50mg group (P = .045, Figure 2) and that Δnocturia during
the ﬁrst 4 weeks may possibly be an important parameter for
the degree of satisfaction (P = .046, Figure 2). We moreover
veriﬁedthecorrelationbetweentheQOLandnocturiascores
at baseline or 4 weeks after 50mg treatment with Spearman’s
rank correlation coeﬃcient analysis in the overall patients
and 75mg group, but it was not signiﬁcant in the 50mg
group. We could not draw a deﬁnite conclusion concerning
this result in the 50mg group due to the small number
of patients, however; Δnocturia was correlated with ΔQOL
both in the 75mg and 50mg groups (rs. = 0.437, P = .011
and rs. = 0.663, P = .036, resp.). These results also suggest
the possible importance of improvement in nocturia for
improvement in QOL by naftopidil. Eﬀectiveness of nafto-
pidil at a high dose for voiding symptoms can be explained
by pharmacokinetics/pharmacodynamics of the agent in
vivo and its eﬀect on α1-adrenoceptor antagonists/α1-
adrenoreceptorsinteraction[13].Storagesymptomsarecon-
sidered to represent those of BPH-related overactive bladder
[14] ,a n dm o s tr e c e n tb a s i cs t u d i e so nα1-adrenoceptor
antagonists/α1-adrenoreceptors in the lower urinary tract
may account for the dose-dependent eﬃcacy of naftopidil
for improving storage symptoms [14, 15]. Unfortunately,
our study cannot clarify the reason for improved storage
symptomsincludingnocturiawithnaftopidil;thecomplexity
of the mechanism of nocturia made us refrain from expli-
cating this phenomenon [16]. The smaller voiding score and
prostatevolumeinthe50mggroupsuggestsanotherpossible
diﬀerence in the etiology of LUTS between the two groups;
LUTS in the 50mg group may be associated with bladder-
related conditions. As described elsewhere, naftopidil is an
agent with relatively high selectivity for α1D-adrenoreceptors
[17]. It has been reported that not only α1A- but also α1D-
adrenoreceptor antagonists eﬀe c t i v e l yt r e a tm a l eL U T Sa n d
BPH-related symptoms, but the α1D-relevant mechanism
has not been fully elucidated. Urinary-function-related α1D-
adrenoreceptors are distributed in the prostate, bladder, and
spinal cord [17]. Alpha1-adrenoreceptors most frequently
expressed in the human bladder are the α1D-type, which has
recently been regarded as an important subtype associated
with LUTS [17]. In a bladder outlet obstruction model using
rats, the increase in bladder detrusor muscle was associated
with the higher expression of α1D-adrenoreceptors both in
mRNA and protein levels [18]. In another study on the cen-
tral nervous system, intrathecally injected naftopidil reduced
the intensity of bladder constriction in rats, suggesting the
relevance of α1D-adrenoreceptors in the spinal cord center
[19]. With frequency/volume analysis and ﬁlling cystome-
try in α1D knockout mice, Chen and colleagues reported
that α1D-adrenoreceptor subtype plays a critical role in
regulating bladder function, theoretically supporting clinical
observations such as eﬀectiveness of naftopidil for treating
storagesymptoms[20].Furtherclinicalandbasicapproaches
are thus warranted to elucidate the various eﬀects of this
agent.
The present study had several limitations. The small
number of participants in the current study led to a limited
capacity. Randomized double-blind studies in a large volume
could have provided higher data quality supported by
a higher evidence level. Also, studies on pharmacokinet-
ics/pharmacodynamics were not performed in our study.
In conclusion, the present study with dose escalation
from 50mg/day to 75mg/day of naftopidil showed that
75mg/day of naftopidil was useful for alleviating storage,
voiding, and postmicturition symptoms in men without
compromising safety. The high score for slow stream at
baseline and unsatisfactory improvement in nocturia with
50mg/day of naftopidil may be important factors for men
with LUTS, who prefer and beneﬁt from dose escalation of
this agent. Further studies are warranted to elucidate the
various eﬀects of naftopidil for male LUTS.
Conﬂict of Interests
The authors declare no conﬂict of interests. This work has
not been funded by any commercial company or organiza-
tion.Advances in Urology 7
Abbreviations
LUTS: Lower urinary tract symptoms
BPH: Benign prostatic hyperplasia
IPSS: International Prostate Symptom Score.
Acknowledgment
The authors thank Ms. Noriko Sekine, Ms. Emiko Sato, Ms.
Chieko Watanabe, and Ms. Eiko Honma for their enthusias-
tic nursing and assistance in data acquisition.
References
[1] P. Abrams, “New words for old: lower urinary tract symptoms
for “ prostatism”,” British Medical Journal, vol. 308, no. 6934,
pp. 929–930, 1994.
[2] P. Abrams, L. Cardozo, M. Fall et al., “The standardisation
of terminology of lower urinary tract function: report from
the standardisation sub-committee of the international conti-
nence society,” Neurourology and Urodynamics, vol. 21, no. 2,
pp. 167–178, 2002.
[3] P. Boyle, C. Robertson, C. Mazzetta et al., “The prevalence
of lower urinary tract symptoms in men and women in four
centres. The UrEpik study,” BJU International,v o l .9 2 ,n o .4 ,
pp. 409–414, 2003.
[4] N. Mittmann, K. Trakas, N. Risebrough, and B. A. Liu,
“Utility scores for chronic conditions in a community-
dwelling population,” PharmacoEconomics,v o l .1 5 ,n o .4 ,p p .
369–376, 1999.
[5] C. J. Girman, S. J. Jacobsen, T. Tsukamoto et al., “Health-
related quality of life associated with lower urinary tract
symptoms in four countries,” Urology, vol. 51, no. 3, pp. 428–
436, 1998.
[6] D. E. Irwin, I. Milsom, S. Hunskaar et al., “Population-based
survey of urinary incontinence, overactive bladder, and other
lower urinary tract symptoms in ﬁve countries: results of the
EPIC study,” European Urology, vol. 50, no. 6, pp. 1306–1315,
2006.
[7] Y. Homma, O. Yamaguchi, and K. Hayashi, “Epidemiologic
surveyoflowerurinarytractsymptomsinJapan,”Urology,vol.
68, no. 3, pp. 560–564, 2006.
[8] R. I. Takei, I. Ikegaki, K. Shibata, G. Tsujimoto, and T. Asano,
“Naftopidil, a novel α-adrenoceptor antagonist, displays selec-
tive inhibition of canine prostatic pressure and high aﬃnity
binding to cloned human α-adrenoceptors,” Japanese Journal
of Pharmacology, vol. 79, no. 4, pp. 447–454, 1999.
[9] K. Akiyama, H. Noto, O. Nishizawa et al., “Eﬀect of KMD-
3213, an α-adrenoceptor antagonist, on the prostatic urethral
pressure and blood pressure in male decerebrate dogs,”
International Journal of Urology, vol. 8, no. 4, pp. 177–183,
2001.
[10] Y. Nishino, T. Masue, K. Miwa, Y. Takahashi, S. Ishihara, and
T. Deguchi, “Comparison of two α-adrenoceptor antagonists,
naftopidil and tamsulosin hydrochloride, in the treatment
of lower urinary tract symptoms with benign prostatic
hyperplasia:arandomizedcrossoverstudy,”BJUInternational,
vol. 97, no. 4, pp. 747–751, 2006.
[11] K. Yasuda, T. Yamanishi, M. Tojo, K. Nagashima, S. Akimoto,
and J. Shimazaki, “Eﬀect of naftopidil on urethral obstruction
in benign prostatic hyperplasia: assessment by urodynamic
studies,” Prostate, vol. 25, no. 1, pp. 46–52, 1994.
[12] Y. Funahashi, R. Hattori, Y. Matsukawa, T. Komatsu, N. Sassa,
andM.Gotoh,“Clinicaleﬃcacyofaloadingdoseofnaftopidil
for patients with benign prostate hyperplasia,” World Journal
of Urology. In press.
[13] Y. Kojima, S. Sasaki, Y. Hayashi et al., “Correlation between
alpha 1-adrenoreceptor subtype mRNA expression level and
eﬃcacy of naftopidil for BPH patients,” Journalof Urology, vol.
171, p. 242, 2004.
[14] A. Komiya, H. Suzuki, Y. Awa et al., “Clinical eﬀect of naf-
topidil on the quality of life of patients with lower urinary
tract symptoms suggestive of benign prostatic hyperplasia: a
prospectivestudy,”InternationalJournalofUrology,vol.17,no.
6, pp. 555–562, 2010.
[15] D. A. Schwinn and C. G. Roehrborn, “α-Adrenoceptor
subtypes and lower urinary tract symptoms,” International
Journal of Urology, vol. 15, no. 3, pp. 193–199, 2008.
[16] M. P. FitzGerald, H. J. Litman, C. L. Link, and J. B. McKinlay,
“The association of nocturia with cardiac disease, diabetes,
body mass index, age and diuretic use: results from the BACH
survey,” Journal of Urology, vol. 177, no. 4, pp. 1385–1389,
2007.
[17] M. C. Michel and W. Vrydag, “Alpha1-, alpha2- and beta-
adrenoceptors in the urinary bladder, urethra and prostate,”
British Journal of Pharmacology, vol. 147, pp. S88–119, 2006.
[18] H. Ishihama, Y. Momota, H. Yanase, X. Wang, W. C. De Groat,
and M. Kawatani, “Activation of α adrenergic receptors in the
rat urothelium facilitates the micturition reﬂex,” Journal of
Urology, vol. 175, no. 1, pp. 358–364, 2006.
[ 1 9 ]C .H a m p e l ,P .C .D o l b e r ,M .P .S m i t he ta l . ,“ M o d u l a t i o no f
bladder α1-adrenergic receptor subtype expression by bladder
outlet obstruction,” Journal of Urology, vol. 167, no. 3, pp.
1513–1521, 2002.
[20] Q. Chen, S. Takahashi, S. Zhong et al., “Function of the lower
urinary tract in mice lacking α- adrenoceptor,” Journal of
Urology, vol. 174, no. 1, pp. 370–374, 2005.